Back
HFA Premium Access

Enalapril, eplerenone or their combination: finding the best paradigm to protect against Doxorubicin-Induced Cardiotoxicity

Session: Poster Session 1 - Basic Science: Co-morbidities
Topic: Cancer/Cardiotoxicity
Speaker: Professor R. Hullin (Lausanne, CH)
Event: HEART FAILURE 2016

Congress Presentation

Add to my library

Like

About the speaker

Professor Roger Hullin

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)
1 presentation
0 follower

4 more presentations in this session

Ranolazine protects from trastuzumab cardiomyopathy

Speaker: Doctor N. Maurea (Naples, IT)

Access
Abstract
Slides
Like
Thumbnail

Sildenafil treatment in a rat model of cancer cachexia

Speaker: Doctor S. Nucera (Catanzaro, IT)

Access
Abstract
Like
Thumbnail

Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity in vitro and in vivo

Speaker: Professor W. Kim (Seoul, KR)

Access
Abstract
Like
Thumbnail

TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin induced cardiotoxicity

Speaker: Assistant Professor M. Trofenciuc (Arad, RO)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 1 - Basic Science: Co-morbidities

Speakers: Professor R. Hullin, Doctor N. Maurea, Doctor S. Nucera, Professor W. Kim, Assistant Professor M. Trofenciuc
Access
Like
Thumbnail

About the event

Image

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources